In episode 48 of Hims House, Jonathan Stern and Patrick Lester (Bayside) are joined by Saad Alam, founder & CEO of Hone Health. The discussion dives into Saad’s personal health journey and the founding of Hone Health during the pandemic. Saad discusses the company’s focus on hormonal health, weight loss, thyroid medications, and new longevity medications. Saad shares insights into diagnostics, the future of primary care, implications of the Meta ad privacy policy changes and FDA advertising crackdown, and the future of the telehealth industry.
00:43 Saad’s personal health journey
02:34 Hone’s products, revenue, competitors
04:29 Enclomiphene vs. clomiphene
09:07 Testosterone market and demographics
14:10 What longevity means
19:25 Lab testing and biomarkers
22:09 Why Hone hasn’t offered GLP-1s
25:14 “Everyone has a Chinese peptide dealer now”
33:53 Which peptides should Hims start with
35:38 Meta ads and the FDA crackdown on ads
40:43 Is primary care in trouble?
47:52 Why Saad is bullish on Hims
Get full access to Hims House at
himshouse.substack.com/subscribe
